

ProBioGen inks next commercial GlymaxX license with Roche

08 January 2020 | News

The GlymaxX® technology for production of afucosylated proteins is universally applicable, simple and potent



ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen's proprietary GlymaxX® technology to boost the antibody's ADCC anti-tumor activity.

The GlymaxX® technology for production of afucosylated proteins is universally applicable, simple and potent. The unique advantage of the GlymaxX® technology is that a single GlymaxX® modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fucosylation level. The technology can easily be integrated in newly developed or already existing cell lines of different origins.